Efficacy of S‐1 after pemetrexed in patients with non‐small cell lung cancer: A retrospective multi‐institutional analysis

BACKGROUND: S‐1 and pemetrexed (PEM) are key treatments for non‐small cell lung cancer (NSCLC). However, the mechanism of anticancer activity of S‐1 and PEM is similar. Cross‐resistance between S‐1 and PEM is of concern. This exploratory study was designed to evaluate the treatment effect of S‐1 fol...

Descripción completa

Detalles Bibliográficos
Autores principales: Takemoto, Shinnosuke, Akagi, Kazumasa, Ono, Sawana, Tomono, Hiromi, Honda, Noritaka, Suyama, Takayuki, Umeyama, Yasuhiro, Dotsu, Yosuke, Taniguchi, Hirokazu, Ogawara, Daiki, Senju, Hiroaki, Gyotoku, Hiroshi, Sugasaki, Nanae, Yamaguchi, Hiroyuki, Nakatomi, Katsumi, Fukuda, Minoru, Mukae, Hiroshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8410557/
https://www.ncbi.nlm.nih.gov/pubmed/34255933
http://dx.doi.org/10.1111/1759-7714.14055

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8410557/
https://www.ncbi.nlm.nih.gov/pubmed/34255933
http://dx.doi.org/10.1111/1759-7714.14055

Ejemplares similares